Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus KELNOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus KELNOR.
ARANELLE vs KELNOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive